Neos Therapeutics Obtains $72,000,000 New Round

  • Feed Type
  • Date
  • Company Name
    Neos Therapeutics
  • Mailing Address
    2940 N Hwy 360 Grand Prairie, TX 75050 USA
  • Company Description
    Neos Therapeutics (NASDAQ: NEOS) is a specialty pharmaceutical company that focuses on time-release technologies. We have developed a broad, cutting-edge portfolio of processes that allow for tailored and independent release profiles of single and multiple ingredients.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The principal purposes of this offering are to increase our financial flexibility, create a public market for our common stock and facilitate our access to public equity markets. We currently intend to use the net proceeds that we will receive from this offering for as follows: approximately $12.1 million for pre-commercialization planning of our three lead product candidates, NT-0102, NT-0202 and NT-0201; approximately $28.7 million for commercialization of our three lead product candidates, if approved; and the remainder for working capital, capital expenditures and general corporate purposes, including investing further in research and development efforts.
  • M&A Terms

Trending on Xconomy